Afinitor everolimus: Phase II data

In an open-label, Japanese Phase II trial in 54 Asian patients with advanced gastric cancer, 10 mg daily Afinitor had a 55% disease control rate at week 8 and resulted in tumor shrinkage in 45% of pat...